Zobrazeno 1 - 10
of 54
pro vyhledávání: ''
Autor:
Esther Pohl-Rescigno, Peter Klare, Gbg, Kristina Lübbe, Michael Untch, Kerstin Rhiem, Carsten Denkert, Jens Huober, Hans Tesch, Andreas Schneeweiss, Sibylle Loibl, Christian Jackisch, Karin Kast, Rita K. Schmutzler, Christine Solbach, Theresa Link, Valentina Nekljudova, L Michel, Peter A. Fasching, Claus Hanusch, Eric Hahnen, Volker Möbus, Ago-B, Jens-Uwe Blohmer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 160
Background GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) i
Autor:
Sophie Postel-Vinay, Capucine Baldini, Jean C. Soria, David Malka, Anas Gazzah, Valérie Boige, Stéphane Champiat, Yolla El-Dakdoukti, Jean M. Michot, Christophe Massard, Antoine Hollebecque, P. Vuagnat, Michel Ducreux, Aurélien Marabelle, Samy Ammari, Andreea Varga, Rastislav Bahleda, Patricia Martin-Romano, Eric Angevin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 137
Background Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Alth
Autor:
Srikala S. Sridhar
Publikováno v:
European journal of cancer (Oxford, England : 1990). 127
Autor:
Éva Remenár, Martin Forster, Judit Kocsis, Magnus T. Dillon, Jonathan Greenberg, Frederic Rolland, Gábor Pajkos, Kevin J. Harrington
Publikováno v:
European journal of cancer (Oxford, England : 1990). 123
Background The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCC
Autor:
Yoon Ji Choi, Hanjong Ahn, Hee Jun Kim, Kyong Hwa Park, Ho Yeong Lim, Kyung Hee Lee, Shinkyo Yoon, Jun Hyuk Hong, Inkeun Park, Bong Seog Kim, Hyo Jin Lee, Jae-Lyun Lee, Bumsik Hong
Publikováno v:
European journal of cancer (Oxford, England : 1990). 127
Purpose Gemcitabine–oxaliplatin (GEMOX) demonstrated mild toxicity and promising effectiveness in patients with advanced urothelial cell cancer (UCC). We investigated the activity and safety of first-line GEMOX compared with gemcitabine–carboplat
Autor:
Margreet G. Franken, John B. A. G. Haanen, B Leeneman, Carin A. Uyl-de Groot, Pieter van Baal, Maria Gheorghe
Publikováno v:
European Journal of Cancer, 123, 58-71. Elsevier Ltd.
Background Although a myriad of novel treatments entered the treatment paradigm for advanced melanoma, there is lack of head-to-head evidence. We conducted a network meta-analysis (NMA) to estimate each treatment's relative effectiveness and safety.
Autor:
Paolo Bossi, Massimiliano Alù, Roberta Depenni, Stefano Cavalieri, Giuseppe Azzarello, Cinzia Baldessari, Carla Codecà, Maria Cossu Rocca, Daris Ferrari, Marco Piccininni, Giorgia Boscolo, Franco Nolè
Publikováno v:
European journal of cancer (Oxford, England : 1990). 115
Aim The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment respons
Autor:
Nadège Corradini, Daniel Orbach, Hélène Sudour-Bonnange, Gwénaëlle Duhil de Bénazé, Claire Berger, Catherine Patte, Brice Fresneau, Cécile Vérité, Hélène Pacquement, Cécile Faure-Conter, Hélène Martelli
Publikováno v:
European journal of cancer (Oxford, England : 1990). 91
Methods French patients (≤18years) treated for dysgerminoma between 1985 and 2005 in TGM-85, 90, 95 protocols were included. Treatment was based on primary unilateral oophorectomy followed by prophylactic lymph node irradiation (1985–1998) or a w
Autor:
Alain Ravaud, Gael Deplanque, Xavier Muracciole, François Goldwasser, Jean Michel Vannetzel, Eric Voog, Corine Teghom, Stéphane Culine, Yann Vano, Jean-Pascal Machiels, Philippe Beuzeboc, Annick Vieillefond, Stéphane Oudard, Thierry Nguyen, Christine Theodore, Jacques-Olivier Bay, Reza Elaidi, Gwenaelle Gravis, Franck Priou, François Radvanyi, Eugeniu Banu, Marie-France Pichon
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(1)
AIM: To investigate the efficacy and safety of gemcitabine and platinum salt, with or without trastuzumab, in patients with locally advanced or metastatic urothelial carcinoma overexpressing Her2. METHODS: The main eligibility criterion was Her2 over
Autor:
Gareth J. Veal, Christophe Bardin, Etienne Chatelut, Dominique Levêque, Nicolas Widmer, Jos H. Beijnen, Angelo Paci, Alain Astier
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(12)
Most anticancer drugs are characterised by a steep dose–response relationship and narrow therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The most relevant PK parameter for cytotoxic drugs is the area unde